Integra LifeSciences Holdings Corp., the Princeton-based medical technology company, has completed its previously announced, $300 million-plus acquisition of ACell Inc., it announced Wednesday.
“Acquiring ACell and its proprietary MatriStem UBM technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges,” CEO and President Peter Arduini said in a prepared statement.
The deal was initially announced in December.
